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Abstract:  Sarcophine-diol  (SD),  one  of  the  structural  modifications  of  sarcophine,  has 
shown  chemopreventive  effects  on  12-dimethylbenz(a)anthracene-initiated  and  12-O- 
tetradecanoylphorbol-13-acetate-promoted skin tumor development in female CD-1 mice. 
The objective of this study was to determine the chemopreventive effects of SD on UVB-
induced skin tumor development in hairless SKH-1 mice, a model more relevant to human 
skin  cancer,  and  to  determine  the  possible  mechanisms  of  action.  Carcinogenesis  was 
initiated and promoted by UVB radiation. Female hairless SKH-1 mice were divided into 
two groups having 27 mice in each group: control and SD treatment. The control group was 
topically treated with 100 µL acetone and SD treatment group was topically treated with 
SD (30 µg/100 µL in acetone) 1 hour before each UVB radiation for 32 weeks. Tumor 
counts were recorded on a weekly basis for 30 weeks. Effects of SD on the expression of 
caspases were investigated to elucidate the possible mechanism of action. The proteins 
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from epidermal homogenates of experimental mice were used for SDS-PAGE and Western 
blotting using specific antibodies against caspase-3, caspase-8 and caspase-9 respectively. 
TUNEL assay was used for determining DNA fragmented apoptotic cells in situ. Results 
showed  that  at  the  end  of  experiment,  tumor  multiplicity  in  control  and  SD  treatment 
groups was 25.8 and 16.5 tumors per mouse respectively. Furthermore, Topical treatment 
of SD induced DNA fragmented apoptotic cells by upgrading the expressions of cleaved 
caspase-3  and  caspase-8.  This  study  clearly  suggested  that  SD  could  be  an  effective 
chemopreventive  agent  for  UVB-induced  skin  cancer  by  inducing  caspase  dependent 
apoptosis. 
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1. Introduction 
 
Non-melanoma  skin  cancer  (NMSC),  including  basal  cell  carcinoma  (BCC)  and  squamous  cell 
carcinoma (SCC) are the most common malignant neoplasms in human [1]. It has been estimated that 
more than one million cases of BCC and SCC are diagnosed each year in the US alone [2], which is 
equivalent to the incidence of malignancies in all other organs combined [3,4]. 
Chronic exposure to ultraviolet (UV) radiation is responsible for about 90% of human NMSCs [5]. 
Over-exposure to UV from the sun can cause sunburn, skin damage and ultimately, skin cancer. Solar 
UV radiation is conventionally divided into UVA (320-400 nm), UVB (280-320 nm) and UVC (200-
280 nm). The UV light that reaches the earth is composed of about 90% UVA and 10% UVB; whereas, 
UVC does not penetrate the earth's atmosphere [6]. In addition, the level of UVB reaching the earth's 
surface is controlled largely by the amount of ozone in the atmosphere [7,8]. Both UVA and UVB are 
being studied for their skin cancer-causing potential, but currently UVB is thought to be the most 
important etiologic factor. Thus, UVB is the most frequently used photocarcinogen in animal studies 
[9,10]. UVB can act in mouse skin models as a complete carcinogen, meaning that UVB can function 
as an initiator as well as a promoter [11,12]. 
These observations suggest that developing effective approaches and novel strategies to prevent 
UVB-caused  human  NMSC  is  imperative  to  the  society.  Recently,  there  has  been  a  considerable 
interest  in the use of marine natural products for the chemopreventive activity against skin tumor 
development [13-18]. Our laboratory has reported that semisynthesis of sarcophine derivatives such as 
sarcophine-diol  (SD,  Figure  1)  showed  high  chemopreventive  effects  against  12-
dimethylbenz(a)anthracene  (DMBA)-initiated  and  12-O-tetradecanoylphorbol-13-acetate  (TPA)-
promoted skin carcinogenesis [17]. The objective of this study was to determine the chemopreventive 
effects  of  SD  on  UVB-induced  skin  tumor  development  in  female  SKH-1  hairless  mice,  an 
experimental model more relevant to human skin cancer development. Tumorigenesis is associated 
with loss of apoptotic death of cells [19]. Accordingly, in the present study, effects of SD treatment on 
apoptosis after UVB exposure to SKH-1 mice were determined to elucidate the possible mechanisms 
of action of SD in the UVB-mouse model. Mar. Drugs 2009, 7                                                  
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Figure 1. The structure of sarcophine-diol (SD). 
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2. Results 
 
SD treatment did not affect body weight gain of SKH-1 mice 
 
There  was  no  significant  difference  in  weight  gain  between  control  and  SD  treatment  groups 
throughout the entire experiment (data are not shown). SD pre-treatment did not show any apparent 
skin toxicity to SKH-1 mice and also did not influence the normal growth and development of the mice 
during the whole experimental period. 
 
SD treatment did not significantly inhibit the incidence of skin tumors in SKH-1 mice 
 
The effects of SD treatment on the incidence of skin tumors in SKH-1 mice are shown in Figure 2. 
Skin tumors appeared in the 10
th week of UVB-promotion phase in both control and SD treatment 
groups. Skin tumor incidence was 100% in both control and SD treatment groups respectively by 23 
weeks of UVB-promotion. Results showed that SD pre-treatment did not have significant (P < 0.05) 
effect on the incidence of tumor development throughout the experiment. 
 
Figure  2.  Effects  of  SD  treatment  on  tumor  incidence  in  SKH-1  mice.  Skin  tumors 
appeared  in  the  10
th  week  of  UVB-promotion  phase  in  both  control  and SD treatment 
groups.  SD  pre-treatment  did  not  significantly  (P  <  0.05)  decrease  the  appearance  of 
tumors throughout the experiment. 
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SD treatment inhibited tumor multiplicity in SKH-1 mice  
 
The effects of SD treatment on tumor multiplicity are shown in Figure 3. The mean number of 
tumors per mouse was 25.8 and 16.5 in control and SD treatment groups respectively accounting for 
36% inhibition in SD treated group at the end of the experiment. Overall, SD pre-treatment resulted in 
a significant (P < 0.05) reduction in tumor multiplicity from 15
th week in the promotion phase to the 
end of experiment (the 30
th week of UVB-promotion). 
 
Figure 3. Effects of SD treatment on tumor multiplicity in SKH-1 mice. SD pre-treatment 
significantly (P < 0.05) decreased tumor multiplicity from 15
th week to 30
th week of UVB-
promotion phase. Each point represents mean number of tumor per mice ± SE derived from 
27 mice. 
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SD treatment inhibited the percent of total tumor area to total back area of SKH-1 mice 
 
The effects of SD treatment on tumor area are presented in Figure 4. As shown in Figure 4, the 
mean ratio of total tumor area to total back area was 18.0% and 5.0% in control and SD treatment 
groups respectively accounting for 73% inhibition in tumor area in SD treated group at the end of the 
experiment (P < 0.05). 
 
Figure 4. Effects of SD treatment on tumor area in SKH-1 mice. Average ratio of total 
tumor area to total back area of the SKH-1 mice.  
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UVB radiation induced squamous cell carcinoma in SKH-1 mice 
 
The histopathological examination of tumor progression was investigated after 30 weeks of the 
promotion. Results suggested that both control and SD treatment group were showing squamous cell 
carcinoma in the skin (pictures not shown). 
 
SD treatment induced caspase-3, -8 expressions but not caspase-9 in SKH-1 mice 
 
Epidermal lysates were collected from mice of both control and SD treatment group with 19 weeks 
of UVB promotion (shortened protocol), when first tumor appeared in both groups. The effects of SD 
treatment on caspase-3 and caspase-8 expressions are shown in Figure 5. According to the density of 
bands, SD treatment increased 1.5 times of the expression of cleaved caspase-3 at 17 KDa. Moreover, 
as shown in Figure 5, the cleaved caspase-8 band at 18 KDa for control group is very faint and can be 
hardly observed, whereas, the band for SD Treated group is very intense and dark. However, the bands 
for  cleaved  caspase-9  in  both  control  and  SD  treated  group  were  not  observed  meaning  that  SD 
treatment did not increase the expression of caspase-9 (data not shown). 
 
Figure 5. Effects of SD treatment on expressions of cleaved caspase-3 and caspase-8 in 
SKH-1 mice. At the end of protocol for mechanistic studies as mentioned in materials and 
methods, proteins were isolated from epidermal tissues of mice; lysates were prepared and 
subjected to Western blot analysis to determine the expression of different proteins. b-actin 
was used to verify equal loading of the samples for each membrane. 
                                                  Control       SD 
Cleaved Caspase-3 (17 KDa)                                   
Cleaved Caspase-8 (18 KDa)                                 
        b-actin                                                       
 
SD treatment increased DNA fragmented apoptotic cells in SKH-1 mice  
 
DNA fragmentation is the biochemical hallmark of apoptosis, an irreversible event that commits the 
cell to die [22,23]. TUNEL staining was used to localize apoptotic cells with DNA fragmentation in 
the mouse skin samples from mechanistic study protocol in situ. As shown in Figure 6A, all the cells 
from  control  group  expressed  green  color,  which  were  normal  cells  without  DNA  fragmentation. 
However,  SD  treatment  for  19  weeks  of  the  promotion  phase  modestly  increased  some  DNA 
fragmented  apoptotic  cells  with  brown  color  nuclear  staining  as  shown  in  Figure  6B.  Thus,  SD 
treatment induced DNA fragmentation of cells in SKH-1 mice.  Mar. Drugs 2009, 7                                                  
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Figure 6. Effects of SD treatment on DNA fragmentation of cells. The skin samples from 
mechanistic studies were used to determine DNA fragmented cells in situ. Normal cells 
show green color and apoptotic cells with DNA fragmentation display brown color nuclear 
staining as showed by an arrow. (A) The image from a control mouse skin and (B) The 
image from a SD treated mouse skin mainly represent four independent observations from 
two mouse skins respectively. 
A 
 
B 
 
 
3. Discussion 
 
In recent years, marine natural products such as sarcophytol A, a cembranoid isolated from the 
Okinawan  soft  coral  Sarcophyton,  have  gained  considerable  attention  as  cancer  chemopreventive 
agents [13-18], Sarcophytol A was studied by the National Cancer Institute at a preclinical trial level 
for  skin  cancer  [14].  However,  the  major  limitation  with  sarcophytol  A  is  its  supply,  since  it  is 
available only in minute quantities in the soft coral [24]. 
Sarcophine,  a  fish  toxin  that  acts  as  the  chemical  defense  system  against  natural  predators  by 
inhibiting various vital enzymes such as cholinesterase and phosphofructokinase, is one of the most 
abundant cembranolides, also isolated from the Red Sea Sarcophyton glaucum with yields up to 3% of 
animal  dry  weight  [14,15,20,25].  SD  and  sarophine-triol  (ST)  are  two  structural  modifications  of 
sarcophine. Studies showed that SD and ST were superior to Sarcophytol A in inhibiting Epstein-Barr Mar. Drugs 2009, 7                                                  
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virus early antigen (EBV-E) activation induced by TPA [15]. Moreover, our laboratory has reported 
that  SD  and  ST  show  chemopreventive  effects  against  skin  carcinogenesis  in  mice  [16-18].  For 
example, ST has been shown to have chemopreventive effects on both chemical- and UVB-induced 
skin  tumor  development  in  mice  by  inducing  expressions  of  caspases  [16,18];  SD  has  showed 
chemopreventive effects on DMBA-initiated and TPA-promoted skin tumor development in female 
CD-1 mice [17]. However, chemopreventive effects of SD have not been investigated on UVB-induced 
skin tumor model, an experimental model more relevant to human skin cancer development.  
In the present study, for the first time we provide clear evidence that topical application of SD (30 
mg/application) has modest chemopreventive effects against UVB-induced skin tumor development in 
female  SKH-1  mice.  SD  treatment  significantly  (P  <  0.05)  decreased  tumor  multiplicity  (36% 
inhibition)  and  the  percent  of  tumor  area  in  mice  (72%  inhibition).  Moreover,  SD  pre-treatment 
inhibited  UVB-induced  skin  tumor  development  in  mice  at  a  very  low  concentration  (30  mg  per 
application) as compared to other reported chemopreventive agents which resulted in similar effects at 
milligram  applications  [21,  26-29].  For  example,  topical  application  of  a-santalol  inhibited  UVB-
induced skin tumor development in mice at 5 mg per application [21,26]; topical application of (-)-
epigallocatechin-3-gallate  (EGCG)  at  1  mg/cm
2  skin  area  per  application  prevented  photo-
carcinogenesis  in  wild-type  (C3H/HeN)  mice  [27];  topical  application  of  silymarin  protect 
photocarcinogenesis in SKH-1 mice at 9 mg per application [28] and silibinin at 9 mg per application 
prevented UV radiation-caused skin damages in SKH-1 hairless mice [29].  
Loss  of  apoptotic  cell  death  is  one  of  the  responsible  for  tumorigenesis  [19].  Apoptosis,  a 
programmed cell death, is carried out by a family of cysteine proteases which are caspases [30]. In a 
classical apoptotic cascade, there are two pathways for apoptosis: extrinsic pathway is related with the 
cleavage of caspase-8 and intrinsic pathway which is mediated by the activation of caspase-9, both of 
which activate caspase-3. Activation of caspase-3 results in the cleavage of the inhibitor of the caspase-
activated  deoxyribonuclease  (ICAD)  and  the  caspase-activated  deoxyribonuclease  (CAD)  becomes 
active leading to DNA fragmentation and apoptotic cell death [31,32]. 
Based on these observations, epidermal lysates of mice from the mechanistic study protocol were 
extracted  to  assess  whether  SD  could  inhibit tumorigenesis in UVB-model by inducing apoptosis. 
Consistent with these notions, the results suggest that SD pre-treatment increased the expressions of 
caspase-3 and caspase-8, and DNA fragmented cells as compared to control. However, SD did not 
increase  the  cleavage  of  caspase-9.  These  findings  are  consistence  with  our  previous  studies  in 
chemical-induced skin cancer mouse model [17]. Therefore, SD treatment in both models may induce 
apoptosis through extrinsic pathway rather than intrinsic pathway. When compared with ST which 
contains one additional hydroxyl group, ST increased the expression of caspase-9 in both chemical- 
and  UVB-induced  skin  tumor  mouse  models  [16,18].  Although,  both  ST  and  SD  are  structural 
modifications of sarcophine and differ from each other just by one hydroxyl group, their mechanisms 
of action are not similar in both models. 
Our  previous  in  vitro  studies  also  investigated  the  mechanisms  of  action  of  SD  in  the  human 
epidermoid  carcinoma  A431  cell  line  [33].  The  results  showed  that  SD  treatment  led  to  a 
concentration-dependent  decrease  in  cell  viability  and  cell  proliferation  in  human  epidermoid 
carcinoma A431 cells as assessed by MTT and BrdU incorporation assays. Moreover, SD treatment Mar. Drugs 2009, 7                                                  
 
 
160
induced a strong apoptosis and significantly (P < 0.05) increased DNA fragmentation by upgrading the 
activity and expression of caspase-3 through activation of upstream caspase-8 in A431 cells. These 
findings are consistent with the results of the current investigation. 
 
4. Experimental Section 
 
Materials and reagents 
 
Sodium  chloride,  SDS  and  phenylmethylsulphonylfluoride  (PMSF)  were  purchased  from  Sigma 
Chemical Co. (St. Louis, MO, USA). Tris(hydroxymethyl)-aminomethane and glycine were purchased 
from USB corporation (Cleveland, OH, USA). Leupepth and pepstatin were from Roche Diagnostics 
GmbH (Mannheim, Germany). Acrylamide was purchased from Bio Rad Laboratories (Hercules, CA, 
CA) and nitrocellulose membrane from Bioexpress (Kaysville, UT, USA). Primary antibody against 
cleaved  caspase-3  was  purchased  from  Cell  Signaling  Technology,  Inc., (Beverly, MA, USA) and 
primary  antibodies  against  caspase-8,  caspase-9  and  b-actin  were  obtained  from  Santa  Cruz 
Biotechnology, Inc. (Santa Cruz, CA, USA). Horseradish peroxidase conjugated goat anti-rabbit and 
anti-mouse secondary antibodies were purchased from BD Biosciences (Rockville, MD, USA). ECL 
Kit was bought from Amersham Biosciences (Piscataway, NJ, USA). TACS TdT in situ apoptosis 
detection kit was from R&D systems (Minneapolis, MN, USA). Other reagents were obtained in their 
highest purity grade available commercially. 
 
Synthesis of SD 
 
Sarcophine  was  isolated  from  the  soft  coral  Sarcophyton  glaucum  by  multiple  extractions  with 
petroleum ether at room temperature as reported [14, 20] at the laboratories of Faculty of Pharmacy, 
Misr International University, Cairo, Egypt. The dried extract was evaporated under reduced pressure 
and chromatographed on silica gel column using hexane: ethyl acetate (1:2) as eluent. Pure sarcophine 
was obtained by crystallization from ethanol. SD was synthesized according to the following procedure: 
sarcophine was reduced to its lactone opened ring analog (1 mmol) to which selenium dioxide (98%, 1 
mmol) in dry 1,4-dioxane (30 mL) was added and the reaction mixture was stirred at room temperature 
for 15 min and followed by TLC to check for completion of reaction. Water was then added to the 
reaction mixture, and the product was extracted with CH2Cl2. Saturated NaHCO3 solution was used to 
wash the CH2Cl2 layer which was dried over anhydrous Na2SO4. The solvent was evaporated and the 
residue was chromatographed on silica gel using hexane: ethyl acetate (1:2) as an eluent to obtain SD 
(90% yield) [14].
 
The structure of SD was fully characterized as shown in Figure 1 by spectroscopic methods and was 
identical to analytical sample prepared according to previous reported method of synthesis [14, 20]. 
Purity was confirmed by HPLC. Mar. Drugs 2009, 7                                                  
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Animals  
 
Female SKH-1 mice were purchased from Charles River Laboratories (Wilmington, MA, USA). All 
mice were housed in the College of Pharmacy animal facility under climate-controlled environment 
with a 12 hours light/dark cycle. Mice were allowed free access to food pellets and water placed inside 
the  food  chamber  on  top  of  the  cage  cover.  The  experimental  protocol  was  approved  by  the 
Institutional Animal Care and Use Committee. 
 
UVB source 
 
The UVB irradiation unit, manufactured by Daavlin Corporation (Bryan, OH, USA) consists of four 
UVB  lamps.  The  exposure  dose  can  be  controlled  by  using  two  Daavlin  flex  control  integrating 
dosimeters. The dose of UVB exposure is expressed in millijoules/cm
2 (mJ/cm
2). 
 
UVB-initiated and UVB-promoted skin tumor development protocol 
 
The tumorigenesis protocol as described by Dwivedi et al. [21] was used. Female SKH-1 mice were 
randomly divided into two groups having 27 mice per group, control and SD treatment. Both initiation 
as well as promotion was induced by UVB radiation (180 mJ/cm
2). During the initiation phase, control 
group was treated with 100 µL of acetone and SD treatment group was treated with 100 µL of SD (30 
mg/100 µL of acetone) 1 h prior to UVB exposure. The treatment and UVB exposure were done every 
day at the same time and was continued for 14 days. During the promotion phase, both control and SD 
treatment  groups  were  treated  in  the  same  way  as  they  were  treated  during  the  initiation  phase. 
However, the treatment was done only twice a week (Tuesday and Friday) and was continued until the 
next 30 weeks for the promotion phase. Tumor counts and group weights were taken once every week. 
 
Effects of SD on tumor area of SKH-1 mice 
 
Pictures  of  the  mice  were  taken  at  the  end  of  tumorigenesis  protocol  (the  30
th  week  of  UVB-
promotion). These digital photographs of the mice were used to calculate the visual surface area for 
each mouse and the tumor associated with each mouse. The boundaries of each tumor was clarified 
using Photoshop CS3 (Adobe Systems, San Jose, CA, USA), and the areas were determined with the 
measure-area feature of Image-Pro Plus 5.1 (Media Cybernetics, Inc., Bethesda, MD, USA). 
 
Histopathological analysis of mouse tumors 
 
Mice were sacrificed by cervical dislocation at the termination of above protocol. Skin collected 
from mice was prepared for histopathological examination by immersion fixation in 10 % neutral 
buffered formalin for several days at room temperature. Fixed tissues were processed for paraffin-wax 
embedding,  sectioned  4  to  6  micrometers  thick,  stained  with  hematoxylin  and  eosin  (HE),  and 
evaluated under light microscope. Mar. Drugs 2009, 7                                                  
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Tumorigenesis protocol for mechanistic studies  
 
Female  SKH-1  mice  were  randomly  divided  into  two  groups,  control  and  SD  treatment.  Both 
initiation as well as promotion was induced by UVB radiation. During the initiation phase, control 
group was treated with 100 µL of acetone and SD treatment was treated with 100 µL of SD (30 mg/100 
µL of acetone) 1 h prior to UVB treatment (180 mJ/cm
2). This was done every day and was continued 
for seven days. One week after the initiation phase, promotion phase was started. During the promotion 
phase, control was treated with 100 µl of acetone and SD treated with 100 µL of SD (30 mg/100 µL of 
acetone) 1 h prior to UVB treatment (100 mJ/cm
2) twice a week (Tuesday and Friday) for 19 weeks. 
 
Preparation of cell lysate for Western blotting 
 
Mice from the mechanistic study protocol described above were sacrificed by cervical dislocation 
and epidermis of mice from both control and SD treated groups was collected. Cell lysate for Western 
blotting and analysis of caspase-3, -8, and -9 expressions were prepared as described earlier by Zhang 
et al. and Kundoor et al. [16-18]. Briefly, the fat and tumors in the skin of these two groups were 
removed  and  then  epidermis  was  homogenized  in  0.1  mM  Tris-HCl  (pH  7.4)  containing  0.15  M 
sodium  chloride.  The  epidermal  homogenate  was  filtered  by  cheesecloth  and  then  filtrate  was 
centrifuged at 10,000 g for 20 min in the Beckman J2-21 Centrifuge. This pellet combined with 5% 
SDS containing 100 mM PMSF, 0.5% leupepth and 0.5% pepstatin was allowed to pass through 25G 
needle, centrifuged at 13,000 g for 20 min and heated in heating block (100 °C) for 5 min. Finally 
proteins were collected and used for determining expressions of caspase-3, -8, and -9 by SDS-PAGE 
and Western blotting. 
 
Western blot analysis of caspase -3, -8, and -9 expressions 
 
Protein concentration was measured in each cell lysate by the protein assay (Pierce, Illinois) with 
albumin as a standard. Equal amount of protein lysates (60 µg) were resolved on SDS-poly-acrylamide 
gels and transferred to nitrocellulose membrane. Membranes were blocked for 1 h in 5% skim milk in 
TBS (10 mM Tris, 100 mM NaCl), and then probed with primary antibodies against caspase-3, -8, and 
-9. The secondary antibodies conjugated to horseradish peroxidase were used for development with the 
enhanced  chemiluminescence  detection  (ECL)  kit.  Western  blots  were  quantified  using  a  UVP 
Biochem Gel Documentation system (UVP, Inc., Upland, California). To ensure equal protein loading, 
each membrane was stripped and reprobed with anti-b-actin antibody. 
 
Determination of DNA fragmented cells on skin sections 
 
To  identify  DNA  fragmentation  of  cells  on  the  skin  samples  of  mice  from  mechanistic  study 
procedure,  TACS  TdT  in  situ  apoptosis  detection  kit  was  used  according  to  the  procedure  of 
manufacturer  (R&D  systems,  Minneapolis,  MN,  USA).  Briefly,  skin  samples  were  first  fixed  to 
prevent the loss of low molecular weight DNA fragments. To make the DNA accessible to the labeling Mar. Drugs 2009, 7                                                  
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enzyme,  the  cell membranes are permeabilized with proteinase K reagent. Endogenous peroxidase 
activity was quenched using hydrogen peroxide. Next, biotinylated nucleotides were incorporated into 
the  3’-OH  ends  of  the  DNA  fragments  by  terminal  deoxynucleotidyl  transferase  (TdT).  The 
biotinylated nucleotides were detected by using streptavidin-horseradish peroxidase conjugate followed 
by  the  substrate,  diaminobenzidine  (DAB).  DAB-stained  samples  were  examined  using  a  light 
microscope. The enzyme reaction generated an insoluble colored precipitate where DNA fragmentation 
occurred. 
 
Statistical analysis 
 
The software INSTAT (Graph Pad, San Diego, CA, USA) was used to analyze the data. Chi Square 
was used for analyzing the data on tumor incidence. Student t-test was applied to compare the tumor 
multiplicity, weight gain, percent of tumor area, caspase-3, and caspase-8 expressions. Significance in 
all the cases was considered at P < 0.05. 
 
5. Conclusions 
 
The results from present study suggest that SD has modest chemopreventive effects at 30 mg per 
application  and  has  an  excellent  potential  to  be  a  potent  chemopreventive  agent  at  higher 
concentrations for the non-melanoma skin cancer development by inducing apoptosis through extrinsic 
pathway. Future studies on dose-response, time-response, and pre-and post-treatment are needed to 
fully explore the skin cancer preventive effects of SD. 
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